Zobrazeno 1 - 10
of 21
pro vyhledávání: '"David J. De La Zerda"'
Autor:
Ivan O. Rosas, Norbert Bräu, Michael Waters, Ronaldo C. Go, Atul Malhotra, Bradley D. Hunter, Sanjay Bhagani, Daniel Skiest, Sinisa Savic, Ivor S. Douglas, Julia Garcia-Diaz, Mariam S. Aziz, Nichola Cooper, Taryn Youngstein, Lorenzo Del Sorbo, David J. De La Zerda, Andrew Ustianowski, Antonio Cubillo Gracian, Kevin G. Blyth, Jordi Carratalà, Bruno François, Thomas Benfield, Derrick Haslem, Paolo Bonfanti, Cor H. van der Leest, Nidhi Rohatgi, Lothar Wiese, Charles Edouard Luyt, Rebecca N. Bauer, Fang Cai, Ivan T. Lee, Balpreet Matharu, Louis Metcalf, Steffen Wildum, Emily Graham, Larry Tsai, Min Bao
Publikováno v:
EClinicalMedicine, Vol 47, Iss , Pp 101409- (2022)
Summary: Background: In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but shortened hospital and intensive care unit stay. Longer-term ef
Externí odkaz:
https://doaj.org/article/0cce1eb2d409455cafdb2877f5cbfad7
Autor:
Christine A. Vu, Kailynn J. DeRonde, Ana D. Vega, Meshell Maxam, Gregory Holt, Yoichiro Natori, Jose Gonzales Zamora, Veronica Salazar, Renata Boatwright, Stephen R. Morris, Daniela de Lima Corvino, Anmary Fernandez Betances, Leah Colucci, James Keegan, Andy Lopez, Andrew Hany Rezk, Yvette Rodriguez, Gabriela M. Moraru, Susanne Doblecki, David J. De La Zerda, Lilian M. Abbo
Publikováno v:
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Due to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with
Externí odkaz:
https://doaj.org/article/4df1660067b9456fa0d9d27a036408b6
Autor:
Sudarshan Rajagopal, Lana Melendres-Groves, Andrew Nelsen, Aaron B. Waxman, Eric Shen, Peter M. Smith, David J. De La Zerda, Amy Case, Shilpa Johri, Christopher S. King, Sandeep Sahay, Hilary M. DuBrock, Steven D. Nathan, Lisa D. Edwards, Victor F. Tapson
Publikováno v:
The Lancet Respiratory Medicine. 9:1266-1274
Summary Background INCREASE was a randomised, placebo-controlled, phase 3 trial that evaluated inhaled treprostinil in patients with interstitial lung disease (ILD) and associated pulmonary hypertension. Treprostinil improved exercise capacity from b
Autor:
Ivan O. Rosas, Norbert Bräu, Michael Waters, Ronaldo C. Go, Atul Malhotra, Bradley D. Hunter, Sanjay Bhagani, Daniel Skiest, Sinisa Savic, Ivor S. Douglas, Julia Garcia-Diaz, Mariam S. Aziz, Nichola Cooper, Taryn Youngstein, Lorenzo Del Sorbo, David J. De La Zerda, Andrew Ustianowski, Antonio Cubillo Gracian, Kevin G. Blyth, Jordi Carratalà, Bruno François, Thomas Benfield, Derrick Haslem, Paolo Bonfanti, Cor H. van der Leest, Nidhi Rohatgi, Lothar Wiese, Charles Edouard Luyt, Rebecca N. Bauer, Fang Cai, Ivan T. Lee, Balpreet Matharu, Louis Metcalf, Steffen Wildum, Emily Graham, Larry Tsai, Min Bao
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Rosas, I O, Bräu, N, Waters, M, Go, R C, Malhotra, A, Hunter, B D, Bhagani, S, Skiest, D, Savic, S, Douglas, I S, Garcia-Diaz, J, Aziz, M S, Cooper, N, Youngstein, T, Sorbo, L D, De La Zerda, D J, Ustianowski, A, Gracian, A C, Blyth, K G, Carratalà, J, François, B, Benfield, T, Haslem, D, Bonfanti, P, van der Leest, C H, Rohatgi, N, Wiese, L, Luyt, C E, Bauer, R N, Cai, F, Lee, I T, Matharu, B, Metcalf, L, Wildum, S, Graham, E, Tsai, L & Bao, M 2022, ' Tocilizumab in patients hospitalised with COVID-19 pneumonia : Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA) ', EClinicalMedicine, vol. 47, 101409 . https://doi.org/10.1016/j.eclinm.2022.101409
Universidad de Barcelona
Rosas, I O, Bräu, N, Waters, M, Go, R C, Malhotra, A, Hunter, B D, Bhagani, S, Skiest, D, Savic, S, Douglas, I S, Garcia-Diaz, J, Aziz, M S, Cooper, N, Youngstein, T, Sorbo, L D, De La Zerda, D J, Ustianowski, A, Gracian, A C, Blyth, K G, Carratalà, J, François, B, Benfield, T, Haslem, D, Bonfanti, P, van der Leest, C H, Rohatgi, N, Wiese, L, Luyt, C E, Bauer, R N, Cai, F, Lee, I T, Matharu, B, Metcalf, L, Wildum, S, Graham, E, Tsai, L & Bao, M 2022, ' Tocilizumab in patients hospitalised with COVID-19 pneumonia : Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA) ', EClinicalMedicine, vol. 47, 101409 . https://doi.org/10.1016/j.eclinm.2022.101409
Background: \ud In COVACTA, a randomised, placebo-controlled trial in patients hospitalised with coronavirus disease-19 (COVID-19), tocilizumab did not improve 28-day mortality, but shortened hospital and intensive care unit stay. Longer-term effects
Autor:
Lorenzo Del Sorbo, Atul Malhotra, Larry Tsai, Helen Spotswood, Ronaldo C. Go, Ivan O. Rosas, Taryn Youngstein, Norbert Bräu, Andrew Ustianowski, Sanjay Bhagani, Min Bao, Sophie Dimonaco, Mariam Aziz, Nichola Cooper, Bradley D Hunter, David J. De La Zerda, Michael F. Waters, Daniel Skiest, Emily Graham, Sinisa Savic, Antonio Cubillo Gracian, Balpreet Matharu, Ivor S. Douglas
Publikováno v:
The New England journal of medicine, vol 384, iss 16
Background Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b63ca1c20584d448f33fd98ff7b410f
https://escholarship.org/uc/item/36k8m3wp
https://escholarship.org/uc/item/36k8m3wp
Autor:
Pete Smith, Andrew Nelsen, Aaron B. Waxman, Eric Shen, Steven D. Nathan, Victor F. Tapson, Lisa D. Edwards, Amy Case, Sandeep Sahay, Hilary M. DuBrock, Lana Melendres-Groves, David J. De La Zerda, Christopher S. King, Sudarshan Rajagopal, Shilpa Johri
Publikováno v:
SSRN Electronic Journal.
Background: INCREASE was a multicenter, randomized, double-blind, placebo-controlled, 16-week study that evaluated the safety and efficacy of inhaled treprostinil in patients with interstitial lung disease and associated pulmonary hypertension (PH-IL
Autor:
Veronica Salazar, Meshell Maxam, Christine A. Vu, Daniela de Lima Corvino, Anmary A Fernandez Betances, Ana D Vega, Yoichiro Natori, Jose Armando Gonzales Zamora, Andrew Rezk, Yvette Rodriguez, Stephen R. Morris, David J. De La Zerda, Susanne Doblecki, Lilian M. Abbo, Leah Colucci, Gabriela M. Moraru, James Keegan, Kailynn DeRonde, Andy Lopez, Renata Boatwright, Gregory E. Holt
Publikováno v:
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Infectious Diseases
BMC Infectious Diseases
BackgroundDue to the lack of proven therapies, we evaluated the effects of early administration of tocilizumab for COVID-19. By inhibition of the IL-6 receptor, tocilizumab may help to mitigate the hyperinflammatory response associated with progressi
Autor:
Michael F. Waters, Lorenzo Del Sorbo, Daniel J. Skiest, Sinisa Savic, Antonio Cubillo Gracian, Bradley D. Hunter, Helen Spotswood, Andrew Ustianowski, Min Bao, Ivan O. Rosas, Larry Tsai, Mariam Aziz, Ivor S. Douglas, Nichola Cooper, Sophie Dimonaco, Norbert Bräu, Balpreet Matharu, Sanjay Bhagani, David J. De La Zerda, Ronaldo C. Go, Atul Malhotra, Emily Graham, Taryn Youngstein
BACKGROUNDCOVID-19 is associated with immune dysregulation and hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody.METHODSPatients hospitalized with severe COVID-19 pneumonia receiving standard care were randomized (2:1) to do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59799bab21f5339258434cebbc658983
https://doi.org/10.1101/2020.08.27.20183442
https://doi.org/10.1101/2020.08.27.20183442
Autor:
David J. De La Zerda, Jeany Villamizar
Publikováno v:
Chest. 158:A1870
Autor:
Tahir Haque, Fahim Pyarali, Alexis Powell, Claudia Martinez, Roumen Iordanov, Gerardo Zablah, Barry E. Hurwitz, David J. De La Zerda
Publikováno v:
Chest. 154:1033A